$569 Million is the total value of Casdin Capital, LLC's 31 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 61.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ONCE | Buy | SPARK THERAPEUTICS INC | $30,831,000 | +98.2% | 463,000 | +53.1% | 5.42% | +43.1% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $29,831,000 | +76.9% | 364,776 | +23.7% | 5.25% | +27.7% |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $29,775,000 | +17.2% | 250,000 | +25.0% | 5.24% | -15.4% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $28,980,000 | +43.0% | 600,000 | +16.5% | 5.10% | +3.3% |
| CDXS | Buy | CODEXIS INC | $22,275,000 | +66.7% | 2,025,000 | +26.6% | 3.92% | +20.4% |
| GNMK | Buy | GENMARK DIAGNOSTICS INC | $20,944,000 | +84.0% | 3,850,000 | +41.0% | 3.68% | +32.9% |
| ILMN | Buy | ILLUMINA INC | $16,904,000 | +75.8% | 71,500 | +62.5% | 2.97% | +27.0% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $15,818,000 | +19.4% | 1,110,000 | +3.0% | 2.78% | -13.8% |
| JNCE | Buy | JOUNCE THERAPEUTICS INC | $14,192,000 | +134.3% | 635,000 | +33.7% | 2.50% | +69.2% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $13,523,000 | +8.2% | 450,000 | +12.5% | 2.38% | -21.9% |
| BGNE | Buy | BEIGENE LTDsponsored adr | $11,760,000 | +568.6% | 70,000 | +288.9% | 2.07% | +383.2% |
| IBB | New | ISHARES TRnasdaq biotech | $10,140,000 | – | 95,000 | +100.0% | 1.78% | – |
| CLVS | Buy | CLOVIS ONCOLOGY INC | $9,372,000 | +8.1% | 177,500 | +39.2% | 1.65% | -21.9% |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $6,171,000 | – | 135,000 | +100.0% | 1.08% | – |
| CTMX | Buy | CYTOMX THERAPEUTICS INC | $5,903,000 | +57.5% | 207,500 | +16.9% | 1.04% | +13.8% |
| NEOG | New | NEOGEN CORP | $4,354,000 | – | 65,000 | +100.0% | 0.77% | – |
| OSUR | New | ORASURE TECHNOLOGIES INC | $4,054,000 | – | 240,000 | +100.0% | 0.71% | – |
| CELG | New | CELGENE CORPcall | $3,568,000 | – | 40,000 | +100.0% | 0.63% | – |
| ZLAB | New | ZAI LAB LTDadr | $2,882,000 | – | 135,000 | +100.0% | 0.51% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $1,740,000 | – | 300,000 | +100.0% | 0.31% | – |
| FIXX | New | HOMOLOGY MEDICINES INC | $1,122,000 | – | 60,000 | +100.0% | 0.20% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 35 | Q2 2024 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 35 | Q2 2024 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| FATE THERAPEUTICS INC | 27 | Q4 2023 | 8.3% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| BIOLIFE SOLUTIONS INC | 25 | Q2 2024 | 14.9% |
| CODEXIS INC | 25 | Q2 2024 | 8.1% |
| SAREPTA THERAPEUTICS INC | 24 | Q2 2024 | 13.6% |
| ILLUMINA INC | 24 | Q2 2024 | 6.0% |
| DENALI THERAPEUTICS INC | 23 | Q2 2024 | 3.7% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Century Therapeutics, Inc. | April 18, 2024 | 5,190,506 | 6.1% |
| MAXCYTE, INC.Sold out | February 14, 2024 | 0 | 0.0% |
| Relay Therapeutics, Inc. | February 14, 2024 | 7,387,943 | 6.0% |
| EQRx, Inc.Sold out | November 15, 2023 | 0 | 0.0% |
| BIOLIFE SOLUTIONS INC | October 24, 2023 | 8,707,165 | 19.5% |
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-29 |
| 4 | 2024-08-26 |
| 4 | 2024-08-21 |
| 4 | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| SC 13D/A | 2024-08-14 |
| 4 | 2024-08-13 |
| 4 | 2024-08-09 |
| 4 | 2024-08-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.